Skip to main content

Table 2 Landmark clinical trials in the development of monoclonal antibodies targeting EGFR

From: Clinical development of targeted and immune based anti-cancer therapies

Drug Name Clinical Trial ID Trial Name Population Comparator Year Sponsor Phase N Median OS (months) Median PFS (months)
Monoclonal antibodies to EGFR
 Cetuximab (Erbitux®)
  Cetuximab (400 mg/m2 initial + 250 mg/m2/week) + cisplatin + vinorelbine NCT00148798 FLEX NSCLC Cisplatin + vinorelbine 2005–2014 Merck KGaA III 1861 11.3 vs 10.1 4.8 vs 4.8
  Cetuximab (400 mg/m2 initial + 250 mg/m2/week) NCT01001377 ASPECCT Metastatic CRC Panitumumab 2010–2017 Amgen III 1010 10.0 vs 10.4 4.4 vs 4.1
  Cetuximab [400/250 mg/m2 (initial/weekly)] + Chemotherapy NCT00122460 EXTREME H&N Cancer Chemotherapy 2004–2011 Merck KGaA III 442 10.1 vs 7.4 5.6 vs 3.3
  Cetuximab [400/200 mg/m2 (initial/weekly)] + FOLFIRI NCT00154102 CRYSTAL Metastatic CRC (KRAS WT) FOLFIRI 2004–2011 Merck KGaA III 1221 23.5 vs 20.0 9.9 vs 8.4
  Cetuximab + 5-FU/FA + oxaliplatin (FOLFOX-4) NCT00125034 OPUS Metastatic CRC (KRAS WT) 5-FU/FA + oxaliplatin 2005–2010 Merck KGaA II 344 22.8 vs 18.5 8.3 vs 7.2
 Panitumumab (Vectibix®)
  Panitumumab (6 mg/kg/2w) + FOLFOX NCT00364013 PRIME Metastatic CRC (WT KRAS) FOLFOX 2006–2013 Amgen III 1183 23.9 vs 19.7 9.6 vs 8.0
  Panitumumab (6 mg/kg/2w) + FOLFOX NCT00364013 PRIME Metastatic CRC (Mutant KRAS) FOLFOX 2006–2013 Amgen III 1183 15.5 vs 19.3 7.3 vs 8.8
  Panitumumab (6 mg/kg/2w) + BSC NCT01412957 ‘0007 Metastatic CRC
(WT RAS)
BSC 2011–2017 Amgen III 377 10.0 vs 6.9 5.2 vs 1.7
 Necitumumab (Portrazza®)
  Necitumumab (800 mg/ m2/3w) + gemcitabine + cisplatin NCT00981058 SQUIRE NSCLC Gemcitabine + cisplatin 2010–2018 Eli Lilly and Company III 1093 11.5 vs 9.9 5.7 vs 5.5
  Necitumumab (500 mg/m2/3w) + Chemotherapy NCT00982111 INSPIRE NSCLC Chemotherapy 2009–2018 Eli Lilly and Company III 633 11.3 vs 11.5 5.6 vs 5.6